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The alternative splicing factor Nova2 regulates
vascular development and lumen formation
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Vascular lumen formation is a fundamental step during angiogenesis; yet, the molecular
mechanisms underlying this process are poorly understood. Recent studies have shown
that neural and vascular systems share common anatomical, functional and molecular
similarities. Here we show that the organization of endothelial lumen is controlled at the
post-transcriptional level by the alternative splicing (AS) regulator Nova2, which was
previously considered to be neural cell-speciﬁc. Nova2 is expressed during angiogenesis and
its depletion disrupts vascular lumen formation in vivo. Similarly, Nova2 depletion in cultured
endothelial cells (ECs) impairs the apical distribution and the downstream signalling of the
Par polarity complex, resulting in altered EC polarity, a process required for vascular lumen
formation. These defects are linked to AS changes of Nova2 target exons affecting the Par
complex and its regulators. Collectively, our results reveal that Nova2 functions as an AS
regulator in angiogenesis and is a novel member of the ‘angioneurins’ family.
DOI: 10.1038/ncomms9479 OPEN
1 FIRC Institute of Molecular Oncology, Via Adamello 16, Milan 20139, Italy. 2 Department of Biosciences, Milan University, Via Celoria 26, Milan 20133, Italy.
3 Istituto di Genetica Molecolare, Consiglio Nazionale delle Ricerche, via Abbiategrasso 207, Pavia 27100, Italy. 4 IUSS—Istituto Universitario di Studi
Superiori, Piazza della Vittoria 15, Pavia 27100, Italy. 5 Dipartimento di Biologia e Biotecnologie, ‘Lazzaro Spallanzani’ - Universita` degli Studi di Pavia, via
Ferrata 9, Pavia 27100, Italy. 6 Division of Vascular Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 171 77,
Sweden. 7 Dipartimento di Oncologia Sperimentale, Istituto Europeo di Oncologia, Milan 20141, Italy. 8 Department of Oncology, San Raffaele Scientiﬁc
Institute, via Olgettina 58, Milan 20132, Italy. 9 Division of Neuroscience and INSPE at San Raffaele Scientiﬁc Institute, via Olgettina 58, Milan 20132, Italy.
10 EMBL/CRG Research Unit in Systems Biology, Centre for Genomic Regulation (CRG), Barcelona 08003, Spain. 11 Universitat Pompeu Fabra (UPF),
Barcelona 08003, Spain. 12 Dipartimento di Scienze della Salute, University of Milan, Milan 20122, Italy. 13 Donnelly Centre for Cellular and Biomolecular
Research, University of Toronto, 160 College Street, Toronto, Ontario, Canada M5S 3E1. 14 Rudbeck Laboratory and Science for Life Laboratory, Department of
Immunology, Genetics and Pathology, Uppsala University, Dag Hammarksjo¨ldsv 20, Uppsala 751 85, Sweden. * These authors contributed equally to this
work. ** These authors jointly supervised this work. Correspondence and requests for materials should be addressed to E.D. (email:
elisabetta.dejana@ifom.eu) or to C.G. (email: arneri@igm.cnr.it).
NATURE COMMUNICATIONS | 6:8479 | DOI: 10.1038/ncomms9479 | www.nature.com/naturecommunications 1
& 2015 Macmillan Publishers Limited. All rights reserved.
I
n adulthood most blood vessels remain quiescent; however, in
conditions of active physiological tissue growth, such as during
embryogenesis or tissue repair, endothelial cells (ECs) migrate
and proliferate to form new vessels. This process, known as
angiogenesis, is also critical for the pathogenesis of several
disorders and to support cancer development and progression1.
Although angiogenesis does not initiate malignancy, it promotes
tumour growth by allowing oxygen and nutrients to reach
proliferating cancer cells. Targeting angiogenesis represents a
particularly promising anticancer therapeutic approach, and
several strategies have been attempted so far2.
Recent studies have highlighted signiﬁcant anatomic, structural
and molecular similarities between the vascular and the nervous
systems3. Both systems possess specialized structures—tip cells at
the forefront of endothelial sprouts and axonal growth cones—
that, through ﬁlopodial extensions, probe the environment for
guidance cues. Molecules regulating these processes have
been termed ‘angioneurins’3. The prototypic angioneurin is the
vascular endothelial growth factor (VEGF), which was originally
discovered as a key angiogenic factor, but subsequently shown to
be important also in the development of the nervous system4.
Since blood vessels and nerves are functionally interdependent, the
malfunctioning of this ‘neurovascular link’ can lead to several
vascular and neuronal disorders3.
Until now, the many molecular pathways regulating vascular
development and angiogenesis have been suggested to act
primarily through the regulation of transcription. However,
recent studies indicate that post-transcriptional and epigenetic
programmes cooperate to confer tissue-speciﬁc vascular
properties.
Alternative splicing (AS) is a molecular process that generates
multiple, distinct mature mRNAs from a primary transcript (pre-
mRNA), leading to the production of protein isoforms with
different structural and functional properties. Since more than
90% of human multiexonic genes undergo AS5,6, this process
represents a major mechanism underlying the expansion of the
proteome from a limited repertoire of genes7,8. AS and
transcription predominantly regulate different subsets of genes
to generate the molecular and cellular complexity of different cell
and tissue types9–11. AS thus provides a versatile, additional layer
of regulation to both establish and maintain fundamental
properties of different cell and tissue types. Despite the
importance of AS, the functional roles of the vast majority of
AS events is not well understood.
While there are several examples of splicing variants with a role
in angiogenesis12–15, the molecular mechanisms responsible for
their production are still unknown. Here we describe a novel role
for Nova2, previously described as neural cell-speciﬁc16, as a key
AS regulator of angiogenesis. Both its expression and the levels of
AS of its target exons are regulated during this process. Through
gain- and loss-of-function approaches in ECs, we show that Nova2
regulates AS of factors belonging to the Par polarity complex and
its regulators. Consequently, vascular lumen formation defects
are developed in zebraﬁsh on nova2 morpholino-mediated
knockdown or clustered regularly interspaced short palindromic
repeat (CRISPR)-induced genetic mutation. Collectively, our
results provide evidence that Nova2 is a new member of the
‘angioneurins’ family, and further highlight an important
biological role for post-transcriptional regulation of exon
networks that contribute to both vascular and neuronal functions.
Results
Nova2 expression and function are regulated in ECs. To
identify splicing regulatory factors (SRFs) involved in endothelial
growth and quiescence, we studied ECs under sparse and
conﬂuent conditions. By mining previously published Affymetrix
gene expression data17 comparing mouse ECs grown at
different densities, we identiﬁed Nova2 as an SRF that is
signiﬁcantly upregulated in conﬂuent versus sparse ECs (fold
change¼ 2.3; P valueo0.05, Dunnett test). This result was
surprising since Nova2 was considered previously to be neural
cell-speciﬁc16.
Nova2 and its paralogue Nova1 are among the best-studied
mammalian tissue-speciﬁc SRFs. Both proteins bind RNA
through KH domains that recognize clusters of YCAY repeats
within the pre-mRNA targets16. These factors, with
indistinguishable biochemical properties but mutually exclusive
expression within the central nervous system (CNS)18, regulate
AS programmes involved in neuronal development and synapse
activity16.
Validating the microarray results, we conﬁrmed Nova2
upregulation in conﬂuent versus sparse ECs using reverse
transcription–quantitative PCR (RT–qPCR; Fig. 1a). By
comparing VE-cadherin-null ECs (VEC-null) with the same cells
reconstituted with VE-cadherin (VEC-positive)17 we also found
that Nova2 upregulation in conﬂuent versus sparse ECs does not
require VE-cadherin expression (Supplementary Fig. 1A). On the
contrary, we found that Nova1 is expressed to a negligible level in
ECs, while both factors are expressed in E15.5 mouse whole brain
that we used as positive control (Fig. 1a), consistent with recently
published results19,20. Moreover, expression of the Muscleblind
family of tissue-speciﬁc AS regulators (Mbnl1, Mbnl2 and Mbnl3)
was not modiﬁed by conﬂuence in ECs (Fig. 1a). We further
conﬁrmed the upregulation of Nova2 in conﬂuent ECs at the
protein level by immunoblotting (Fig. 1b). Comparable results
were obtained by using another EC line (adult ECs from the
mouse lung) under sparse and conﬂuent conditions
(Supplementary Fig. 1B). Notably, as in the case of mouse
cortex (Fig. 1b) and in human neuroblastoma SH-SY5Y cells
(Supplementary Fig. 1C), in ECs the anti-Nova2-speciﬁc antibody
recognized two immunoreactive bands at 50–55 and 70–80 kDa,
as previously reported18. In agreement with available RNA
sequencing (RNAseq) data (Supplementary Fig. 1D), we found
that Nova2 is also expressed in primary human umbilical vein
endothelial cells (HUVECs) and that its levels decreased when
HUVECs were grown as sparse (Fig. 1c). Moreover, Nova2
expression increased during endothelial differentiation of mouse
embryonic stem (ES) cells (Fig. 1d), or in adult ECs as compared
with embryo or fetal ECs (Fig. 1e). Importantly, Nova2 expression
correlated with AS changes of its known target Ank3: (i) in sparse
versus conﬂuent ECs, (ii) during endothelial differentiation of ES
cells and (iii) in ECs of different origin (Fig. 1f) and AS of this
target parallels that observed in brain of Nova2-null mice21.
Taken together, these data suggest that Nova2 expression and
function may play a role in vascular maturation.
To conﬁrm the vascular expression of Nova2 in a more
physiological context, we analysed the postnatal mouse retina,
which develops a stereotypical vascular pattern following a
well-deﬁned sequence of events22. In the retina, we found
that Nova2-positive nuclei were reduced but still present in
the ECs at the sprouting front as compared with the central
part of the retina where the majority of ECs of the mature
vessels (arteries and veins) and capillaries were Nova2-positive
(Fig. 2a,b and Supplementary Fig. 2A). In addition, we
found the speciﬁc nuclear expression of Nova2 in ECs present
in the vessels of different tissues, such as normal human thyroid,
skin, bladder, colon and prostate (Fig. 2c and Supplementary
Fig. 2B).
Collectively, these data indicate that Nova2 is not exclusively
expressed in cells of the nervous system, but it is also present in
ECs of different types of vessels.
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Nova2 regulates the endothelial apical–basal polarity. An
important functional similarity in the development of the vas-
cular and nervous systems is the establishment of the apical–basal
polarity, as this is a crucial event for the organization of the
vascular lumen and for axon guidance23,24 respectively. Notably,
the partitioning-defective (Par) polarity complex is a key
determinant of cell polarity in both systems23,24. The speciﬁc
localization and activity of the Par polarity complex involve the
association of four key components: Par3, Par6, the small GTPase
Cdc42 and the atypical protein kinase C (PKCz). In addition, the
small GTPases Rac1 and Rap1 are important regulators of the Par
complex during organization of the vascular lumen23,25.
To investigate the role of Nova2 in the endothelium as a
possible regulator of vascular development, we generated stable
Nova2 knockdown ECs (Fig. 3a). Intriguingly, we found that
depletion of Nova2 expression impairs EC polarity. As shown in
Fig. 3b, in two-dimensional (2D) cultures, Nova2 knockdown
altered the subcellular localization of the apical surface marker
podocalyxin (Podxl) that was distributed all over the cell
membrane and also to the basal surface. These ﬁndings prompted
us to examine whether silencing of Nova2 alters the junctional
staining and/or activity of components of the Par polarity
complex. Nova2-depleted ECs displayed impaired junctional
distribution of Par3, a multiscaffold protein that promotes the
assembly of the Par complex (Fig. 3c). Interestingly, Nova2
knockdown in ECs caused reduced levels of active (GTP-bound)
Cdc42 (Fig. 3d), whose association with the Par complex is
induced during EC lumen formation26. Accordingly, we
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Figure 1 | Nova2 expression levels and AS of its target are regulated in ECs. (a) RT–qPCR analysis of Nova2 and Nova1mRNA expression levels in mouse
ECs grown as conﬂuent or sparse (left), in E9.5 and E15.5 mouse whole brain (centre), and RT–qPCR analysis of Muscleblind family members (Mbnl1,Mbnl2
and Mbnl3) in mouse ECs grown at different densities (right). (b) Immunoblotting analysis of Nova2 levels in mouse conﬂuent and sparse ECs (left panel;
Tubulin as the loading control) and in conﬂuent ECs and the mouse brain cortex (right panel; GAPDH as loading control). (c) Nova2 mRNA and protein
expression levels in HUVECs grown at different densities. (d) RT–qPCR analysis of Nova2 during endothelial differentiation of mouse ES cells at the
indicated times. (e) Immunoblotting analysis of Nova2 in mouse EC lines derived from whole embryo, fetal heart and adult lung; Actin as the loading
control. In all histograms, error bars indicate ±s.d. calculated from three independent experiments (n¼ 3). (f) RT–PCR analysis of AS of a known Nova2
target (Ankyrin3/Ank3) in mouse ECs (conﬂuent and sparse; left), during endothelial differentiation of mouse ES cells (centre) and in mouse ECs of
different origins (right). The schematic representation of the mouse gene structure (AS exon in grey; constitutive exons in black), the YCAY cluster
predicted to function as Nova2 silencer (blue dot) and the Nova2-regulated exon-skipping event (blue bars) are also shown. NISS, Nova intronic splicing
silencer. The percentage of exon inclusion is shown. Asterisk indicates a nonspeciﬁc PCR product.
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Figure 2 | Nova2 is expressed in the vascular endothelium in vivo. (a) Immunoﬂuorescence analysis of Nova2 (green), the endothelial markers CD31
(red) and ERG (blue, transcription factor) in whole-mounted postnatal (P6) mouse retina. Optical sections captured using confocal microscopy display
large vessels in the central retina region (a,b,d,e) and sprouting ECs in the leading edge of the growing vasculature (c,f). Arrows indicate neural cells of the
retina and ECs of vessels expressing Nova2 (scale bar, 50mm). (b) Quantiﬁcation of Nova2 signal. ERG staining has been segmented with threshold 350–
4,096, and segmented images have been ﬁltered to remove speckles and outliers (radius 25). Segmentation results have been used to ﬁlter Nova2 staining
to isolate EC nuclear staining (scale bar, 50mm). Chart shows average signals (error bars indicate mean ±s.d.; asterisks P valueo0.05, two-tailed t-test
assuming unequal variances; n¼ 2). (c) IHC of Nova2 in normal human thyroid (i), skin (ii) and bladder (iii) and IHC of Nova2 and the endothelial marker
CD31 in normal human colon (iv, v). Arrows indicate Nova2 nuclear staining of ECs in the blood vessels (scale bar, 100 mm).
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determined that phosphorylation of PKCz, a Cdc42-GTP-
activated protein27, is also reduced in Nova2-depleted ECs
(Fig. 3d). Moreover, Nova2 knockdown ECs were characterized
by reduced levels of phosphorylated Pak4 (p21-activated kinase;
Fig. 3d), one of the main Cdc42 downstream effectors28.
EC polarization correlates with lumen formation25,29. Thus, to
test whether Nova2 is required for the formation of the
endothelial lumen, we have carried out its knockdown in
primary HUVECs that, when are cultured in three-dimensional
(3D) collagen gel, rapidly organize into a network of hollow
structures30. As shown in Fig. 3e, control HUVEC cells forming
vascular-like structures were correctly polarized with Podxl and
collagen IV localized to the apical and basal surfaces, respectively.
On the contrary, knockdown of Nova2 resulted in the formation
of capillary-like tubular networks with irregular lumen and a
non-polarized distribution of endothelial Podxl and collagen IV.
These results strongly suggest that Nova2 splicing factor is crucial
for EC morphogenesis.
Recently, the Par polarity complex has been shown to regulate
endothelial cell-cell contacts and affect migratory behaviour25,31.
In agreement with these observations we found that silencing of
Nova2 affected junctional clustering of VEC and b-catenin since
the architecture of cell–cell boundaries was partially disorganized
in Nova2 knockdown ECs (Supplementary Fig. 3A). Cell polarity
is also established during directional cell migration, where
cytoskeletal, adhesive and signalling molecules are distributed
asymmetrically. We found that Nova2 knockdown affected the
collective behaviour of migrating ECs. During wound closure,
migrating ECs depleted of Nova2 have in part lost their contacts
with neighbouring cells positioned at the back (Supplementary
Fig. 3B). The leading edge was more tortuous compared with
control ECs (Supplementary Fig. 3B). Finally, given the junctional
alterations induced by Nova2 knockdown, we tested whether
endothelial permeability was also modiﬁed. We found that the
permeability of conﬂuent endothelial monolayers was indeed
increased upon Nova2 depletion (Supplementary Fig. 3C).
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Figure 3 | Nova2 is required for the EC polarization. (a) Nova2mRNA levels in knockdown mouse ECs (grown as conﬂuent). The Nova2 protein level was
analysed by immunoblotting using an anti-Nova2 antibody (Tubulin as loading control). (b) Immunoﬂuorescence (IF) analysis of Podocalyxin (Podxl, green)
and DAPI (blue) in 2D culture of control (Ctr) and Nova2-depleted ECs. Podxl is often distributed to the basal (arrows) instead of the apical surface
(arrowheads) in Nova2-silenced ECs (confocal sections, z axis; scale bar, 25 mm). (c) IF analysis of Par3 (red) and DAPI (blue) in Ctr or Nova2 knockdown
ECs. Arrows indicate altered and fragmented junctional staining of Par3 (bar 20mm). (d) In vitro pull down of GTP-bound Cdc42 in Ctr and Nova2-silenced
ECs. Immunoblotting for the phosphorylation status of PKCz and Pak4 is also shown. (e) Left: Nova2 mRNA levels in knockdown HUVECs. The Nova2
protein level was analysed by immunoblotting using an anti-Nova2 antibody (GAPDH as the loading control). Right: in 3D collagen gel, control HUVECs
form vascular structures with a central lumen (asterisk) and apical Podxl and basal collagen IV (Coll IV) proper localization (arrowheads and arrows,
respectively), whereas Nova2-silenced HUVECs are not correctly polarized (scale bar, 20mm). Error bars indicate mean ±s.d. calculated from three
independent experiments (n¼ 3).
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To comprehensively identify AS events regulated by
Nova2 in the endothelium, we performed high-throughput
RNAseq of two biological replicates of Nova2 knockdown and
control ECs. We used vast-tools32 to identify and quantify all
major types of AS events. vast-tools maps RNAseq reads to
comprehensive sets of annotated and novel splice junctions to
derive conﬁdent estimates of the percentage of alternative
sequence inclusion in a given sample. We identiﬁed 365 AS
events affected by Nova2 depletion, including 188 (51.5%)
cassette exons (Supplementary Fig. 4, Supplementary Table 1
and see Supplementary Methods for details). Gene Ontology
(GO) analyses of AS events predicted to generate alternative
protein isoforms (41% of all AS events and 64% of cassette
exons; Supplementary Fig. 5) showed a signiﬁcant enrichment for
genes involved in cytoskeleton and cell adhesion (including
tight and adherens junctions, and integrin binding), consistent
with the phenotypes described above (Supplementary Table 2). In
addition, the strongest enriched functional terms corresponded to
chromatin remodelling and regulators, suggesting a multilayered
impact of Nova2 regulation on endothelial formation. Finally,
we also observed multiple GO terms related to neuronal
differentiation and function (for example, neurogenesis,
synapsis, axon part and calcium transport), similar to those
reported for Nova-regulated genes in the brain16. Indeed,
comparison of differentially included cassette exons in genes
expressed in both neurons and ECs (see Supplementary Methods)
revealed a highly signiﬁcant overlap between alternative exons
predicted to be regulated by Nova proteins in the brain33
and those showing changes in inclusion levels upon Nova2
knockdown in the endothelium (P¼ 1.93e 11, hypergeometric
test; Supplementary Fig. 6; Supplementary Table 3), despite
the very different approaches used in the two studies (see
Supplementary Materials for details).
These newly identiﬁed Nova2 targets expanded the list of
previously known targets involved in apical–basal polarity, actin
polymerization dynamics and cytoskeletal remodelling, important
processes associated with cell polarity, cell shape, motility and
adhesion (Supplementary Tables 4 and 5). Thus, to conﬁrm a
possible molecular link between these AS events and the
phenotypes described above, we analysed AS changes in selected
targets using RNA extracted from Nova2 knockdown ECs
(Fig. 4a). Reduced Nova2 expression in ECs resulted in altered
AS of transcripts encoding Par3, and regulators of Par activity or
localization, including Magi1, which recruits Rap1 at junctions34,
Rap1GAP (Rap1 inhibitor)35, Pix-a, Dock6, Dock9 and DBS
(Cdc42 activators)36–38 (Fig. 4a and Supplementary Fig. 7).
Importantly, these AS changes parallel to those observed in the
brain of Nova2-null mice16,33, or in two stages of brain
development (Supplementary Fig. 8A) characterized by different
Nova2 expression levels (Fig. 1a). We conﬁrmed the Nova2-
dependent AS of target transcripts in RNA samples extracted
from Nova2-overexpressing ECs (Fig. 4a, Supplementary Fig. 7
and Supplementary Fig. 8B). Notably, the direction of the
observed AS changes is consistent with the position of Nova2-
binding sites (YCAY; Fig. 4a and Supplementary Fig. 7), as
previously reported16.
Our data suggest that in cultured ECs Nova2 establishes EC
polarity by controlling Par3 localization and by regulating the
activity of Cdc42. To begin to address the functional relevance of
the AS events regulated by Nova2 in ECs, we focused on the
Cdc42 activator Pix-a (ref. 36). Our results indicate that Nova2
promotes the production of a speciﬁc Pix-a AS isoform lacking
exon 17 (Pix-a-D17; Fig. 4a). Intriguingly, we found that
Pix-a-D17 is more efﬁcient than the Pix-a isoform containing
exon 17 (Pix-a-FL) in rescuing the defect of Cdc42 activity caused
by Nova2 knockdown (Fig. 4b).
Collectively, these results provide evidence that Nova2 is
required for EC polarity and that it acts by inducing AS of a set of
key effectors of cell polarity.
Nova2 promotes vascular lumen formation in vivo. Since EC
polarity regulates vascular lumen formation, we tested whether
vascular development was affected in the absence of Nova2. To
this end, we investigated the role of Nova2 in the embryos and
larvae of zebraﬁsh, which constitutes a unique and powerful
model to study vertebrate vascular development39. Importantly,
the Nova2 RNA-binding domain is 94% identical between
zebraﬁsh and human40, and we found that a zebraﬁsh Nova2
orthologous gene (nova2) is expressed in the vasculature during
development in addition to CNS (Fig. 5a). To assess the role of
nova2 in zebraﬁsh, we performed a morpholino-mediated
knockdown of its expression. To speciﬁcally visualize the
developing blood vessels, we injected morpholino oligos into
transgenic embryos expressing the enhanced green ﬂuorescent
protein (EGFP) gene under the control of the endothelial-speciﬁc
promoter ﬂi1a (Tg(ﬂi1a:EGFP)y1)41. We used a morpholino
targeting the start codon of zebraﬁsh nova2 (MO-nova2) to block
translation of both maternal and zygotic nova2 mRNAs. While
embryos injected with a control morpholino displayed a normal
morphology, more than 90% of nova2morphant embryos showed
defects at the level of the forming blood vessels. Moreover, during
early embryogenesis the pattern of some intersomitic vessels
(ISVs) displayed extra-branching formation and a delay in the
connection with the dorsal longitudinal anastomotic vessel
(Fig. 5b). Confocal microscopy analysis conﬁrmed that nova2
knockdown resulted in altered lumen size of both cephalic vessels
and of main trunk blood vessels (Fig. 5b,c). To visualize and
further characterize the phenotype at the level of the dorsal aorta
and posterior cardinal vein, we performed a morphological
analysis using transversal parafﬁn sections stained with
haematoxylin–eosin of embryos at different developmental
stages (Fig. 5d). The analysis showed that in most of nova2
morphants the lumen of the dorsal aorta had a larger diameter if
compared with controls, through all developmental stages
analysed. The lumen of the posterior cardinal vein appeared
irregular along the length of the trunk, with areas of enlargement
but also few restrictions (Fig. 5d). Furthermore, starting from 2
days of development, even ISVs display an enlarged lumen
(Supplementary Fig. 9A). To better characterize the phenotype of
nova2 morphants at the level of ISVs during the angiogenic
process, we performed an in vivo time lapse imaging assay. As
shown in Supplementary Movies 1–3 in nova2 morphant
embryos the apical cells of some ISVs develop many more
ﬁlopodia and could barely reach the dorsal longitudinal
anastomotic vessel. Importantly, co-injection of nova2 mutants
with a morpholino-resistant zebraﬁsh nova2 mRNA rescued, in
more than 60% of the injected embryos, the morphological
phenotype of the vessels, conﬁrming the speciﬁcity of the effects
(Fig. 5b–d and Supplementary Movies 1–3). The abnormal
phenotype of blood vessels observed in nova2 morphants was not
due to haemodynamic problems, since at 48 h post fertilization
(hpf) the heart appeared normal for size, shape and beat
(Supplementary Movies 4 and 5). In addition, EC proliferation
and apoptosis were not signiﬁcantly modiﬁed in the morphants
(Supplementary Fig. 9B,C). Collectively, these data indicate that
in vivo nova2 is required for proper vascular morphogenesis and
for the formation of a correct vascular lumen.
Since Par complex members and regulators identiﬁed as Nova2
targets have putative orthologues in zebraﬁsh, we analysed their
AS using RNA extracted from ctr and nova2 morphants. Of the
investigated pre-mRNAs (Fig. 4a), four (Rap1GAP, Pix-a, DBS
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and Dock6) are alternatively spliced in zebraﬁsh (Fig. 5e).
Interestingly, in all cases nova2 knockdown alters exon inclusion
levels (Fig. 5e) in the direction predicted by the position of
putative Nova-binding motifs21 (Supplementary Fig. 10).
Importantly, aberrant AS events of nova2 morphants were
rescued by co-injection of nova2 mRNA (Fig. 5e). Of note, we
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found that some nova2 targets (see, for instance, Rap1gap and
Pix-a, Supplementary Fig. 9C) are not expressed at the same level
in the different types of vessels suggesting that the effects of the
knockdown of nova2 may have different morphological and
functional consequences along the vascular tree.
To assess the apical–basal cell polarity in nova2 morphant
embryos, we analysed the localization of Podocalyxin (Podxl2).
As shown in Fig. 6a, in ctr embryos Podxl2 is localized at the
apical region of the ECs forming ISVs, while in nova2 morphants
Podxl2 is mislocalized in ECs of the ISVs. Moreover, this defect
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persisted at late developmental stage (Supplementary Fig. 9A).
Likewise, altered Podxl2 localization was also observed in dorsal
aorta of nova2 morphants (Fig. 6a), suggesting an altered
establishment of apical–basal polarity. Again, co-injection of
nova2 mRNA rescued Podxl2 localization in ECs (Fig. 6a).
Since Nova2 is expressed in neurons as well as in ECs, and these
cells inﬂuence their reciprocal differentiation and development42,
it was important to address whether the vascular phenotype of
nova2morphants was due to alterations in the nervous or vascular
systems. To do this, we used a morpholino-resistant zebraﬁsh
nova2 cDNA, fused with the red ﬂuorescent protein mCherry,
under the control of the vasculature-speciﬁc ﬂi1a promoter
(Fig. 6b). The vascular defects in nova2 morphants were restored
by the mosaic transient expression in the vascular endothelium of
morpholino-resistant nova2 cDNA (Fig. 6b–d). Moreover, by
generating a zebraﬁsh transgenic line, which stably expresses
morpholino-resistant nova2-mCherry in the vascular endothelium,
we found that injection of MO-nova2 did not signiﬁcantly alter
blood vasculature morphology (Fig. 6e), indicating that the
vascular phenotype of nova2 morphants is cell autonomous.
To independently validate our ﬁndings, we used CRISPRs
genome engineering43 to generate genetic nova2 mutant ﬁsh
(Supplementary Fig. 11A and see Methods for details). The
characterization of nova2 mutants strongly supported our results
and conclusions obtained using MO-mediated nova2 knockdown
(Supplementary Fig. 11). In particular, nova2 homozygous
mutants displayed overlapping defects with nova2 morphants,
such as shortening of the anteroposterior body axis, reduced head
size, curved trunk and slight pericardial oedema (Supplementary
Fig. 11B). Moreover, we observed that nova2 mutants do not
develop the swim bladder and display a strong haemorrhagic
phenotype visible both at the level of the head and trunk
(Supplementary Fig. 11C,D). Notably, similar to Nova knockout
mice44,45, zebraﬁsh nova2 mutant embryos displayed paralysis. In
particular, they have severe difﬁculty in swimming (probably
because of motor–neuronal dysfunction) and died 7–10 days post
fertilization, whereas there was no abnormal phenotype in nova2
heterozygote mutant embryos. Confocal microscopic analyses
performed on the nova2mutants transgenic for kdr:EGFP showed
that many blood vessels had an enlarged lumen size, both in the
head and in the trunk (Supplementary Fig. 11E), as observed in
nova2 morphant embryos. Similar ﬁndings were obtained by
histological analysis (Supplementary Fig. 11F). Finally, nova2
mutants displayed AS changes (Supplementary Fig. 11G) that are
comparable to those in nova2 morphants.
Collectively, our results show that Nova2 controls the
development of the vascular system in vivo by modulating
endothelial polarity and lumen formation.
Discussion
Here we report that AS regulation orchestrates some important
aspects of EC biology. In particular, our data demonstrate that the
AS factor Nova2, known to be neural cell-speciﬁc16, is also
expressed in the vascular endothelium and plays a relevant role in
vascular morphogenesis.
In spite of its importance, our current understanding of the
mechanisms underlying vascular tubulogenesis is only beginning
to be unravelled23,25,29. We have shown that Nova2 acts as a post-
transcriptional regulator of the molecular mechanisms involved
in the organization of the vascular lumen. In zebraﬁsh, depletion
and genetic knockout of nova2 prevents proper formation of the
lumen of blood vessels and also results in defects in EC
polarization. Interestingly, in avascular organisms, such as
Drosophila melanogaster, the Nova homologue (Pasilla, ps), is
not expressed in the brain, but instead is expressed at high levels
in salivary glands and several other non-neuronal tissues46,47.
Notably, ps mutants have altered apical secretion and are
characterized by developmental defects of the salivary gland
including regions of lumen alteration46. This type of morphology,
with a severely altered lumen, is somehow reminiscent of the
morphology of the zebraﬁsh vasculature observed on nova2
depletion. Recently, several regulators of salivary gland lumen
formation (such as Cdc42, Pak proteins and cadherins) have been
identiﬁed in Drosophila48. Intriguingly, they are also implicated in
vascular lumenogenesis23 and, more importantly, regulators of
their activity and localization are known Nova2 AS targets33.
Our data show that, in cultured ECs, Nova2 establishes EC
polarity by controlling Par3 localization, the activity of Cdc42 and
the phosphorylated state of PKCz. Notably, signalling down-
stream of Cdc42 is impaired in the absence of Nova2, as the active
form of PKCz and Pak4 are reduced in Nova2-depleted ECs.
Interestingly, Pak4 phosphorylation correlates with EC lumen
formation and RNA interference-mediated suppression of Pak4
strongly inhibits these processes26. Similarly, depletion of Nova2
impairs the establishment of EC polarity and the organization of
the vascular lumen. These defects are associated with aberrant AS
of pre-mRNAs encoding factors belonging to the Par polarity
complex and its regulators.
Par complex and downstream effectors play important roles in
regulating cell–cell adhesions25, in controlling the organization
of the microtubule cytoskeleton49, and in promoting
directional, collective cell migration31. Strikingly, we found that
downregulation of Nova2 affected the architecture of cell–cell
boundaries and the behaviour of migrating ECs. In particular, in
wound closure Nova2-depleted ECs failed to move in a cohesive
manner with the lack of coordination in the direction of cell
movement suggesting that, in addition to its role on lumen
Figure 5 | Nova2 is required for vascular lumen formation in zebraﬁsh. (a) In situ hybridization of different zebraﬁsh developmental stages showed Nova2
expression in the pericardium (p in e), in the trunk vessels (f,i) of 48 hpf embryos and in the CNS of 24 (g) and 48 hpf embryos (h,ii; scale bars, 250 mm in
a,b; 125mm in c,d,g,h); 50mm in e,f; 25mm for vibratome sections i,ii). (b) Lateral views of the head and trunk of 28 hpf Tg(ﬂi1a:EGFP)y1 embryos, expressing
the EGFP under the endothelial-speciﬁc promoter ﬂi1a, injected with control (ctr) or morpholino against nova2 (MO-nova2). Nova2 knockdown results in
lumen defects of lateral dorsal aorta (LDA), middle cerebral vein (MCeV) and primordial hindbrain channels (PHBC; compare red and/or white bars length
between ctr and nova2 morphants). The ISVs display extra-branching formation (*) and a delay in the connection with the dorsal longitudinal anastomotic
vessel (DLAV). Co-injection of a morpholino-resistant zebraﬁsh nova2 RNA (MO-nova2þ nova2) rescues the vascular defects. (c) Confocal analysis of the
blood vessels in the trunk region of 28-hpf embryos (lateral views); nova2 morphants display enlarged lumen (white bars) of the dorsal aorta (scale bar,
50mm). (d) High magniﬁcations of parafﬁn 10mm transversal sections, stained with haematoxylin–eosin, of the trunk region of 1- and 2-day embryos
(dashed black squares in i,ii) highlighted alterations of the lumen size of the dorsal aorta and PCV in more than 90% of nova2 morphants. Abnormal
phenotype was rescued by co-injection of nova2 mRNA (scale bar, 50mm). e, eye; g, gut; h, hindbrain; m, midbrain; n, notochord; s, somite; sc, spinal cord;
t, telencephalon; y, yolk; AAs, mandibular arches; PMBC, primordial midbrain channel. (e) Nova2 knockdown alters the AS of its targets (24 hpf) that is
corrected by the co-injection of nova2 mRNA (28 hpf). The percentage of exon inclusion is indicated (grey, AS exon); Dock6 as in Fig. 4, DBS is the ratio
26þ 27/total. Asterisk, novel DBS AS variant containing 75 nt (exon 27b: ACGCAGGTCCTCACATCACTCTCACCCGAGTGAGATGGCTGAGCACTTC
TAGTCTGTTGCAGACTAAACGCAGAG) of intron 27.
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blood vessels (scale bar, 250mm). (c) Endothelial-autonomous rescue of nova2 morphants. PTol2ﬂi1ep:mCherry-nova2 plasmid was co-injected with the
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for nova2, respectively). (d) ISV of the trunk expressing nova2 (arrowheads) showed a normal pattern and developed a correct lumen, whereas an adjacent
ISV (arrows), negative for nova2 expression, was not formed properly, so that it failed to reach DLAV (scale bar, 30mm). (e) Lateral view of 28-hpf
transgenic embryos injected with the MO-nova2. Embryo showed in the upper row expresses in the vessel endothelium only GFP, whereas the embryo
showed in the lower row expresses also a morpholino-resistant nova2 cDNA fused with mCherry. The presence of nova2 in the vessel endothelium is
sufﬁcient to preserve vessel morphology of nova2 morphant embryos (scale bar, 50mm).
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formation, Nova2 expression might also control adhesion signals
and the directional migration of ECs.
Our current lack of knowledge of the functional implications of
most AS events makes it difﬁcult to interpret the global impact of
the AS changes we have identiﬁed. Moreover, it is plausible that
additional AS events are regulated by Nova2 in ECs. Nevertheless,
we found that the alteration in Cdc42 activity in Nova2
knockdown ECs is preferentially reverted by overexpression of
a speciﬁc AS isoform of Pix-a (Pix-a-D17) regulated by Nova2,
indicating that AS of this gene plays an important role in Cdc42
activation.
We found Nova2-dependent AS regulation of zebraﬁsh
orthologous genes encoding polarity regulators. Among these,
there are well-characterized activators (Pix-a, Dock6 and DBS) of
Cdc42, which—in turn—plays an essential role in controlling
lumen formation in vitro and in vivo26,48,50–52.
Remarkably, Nova2-regulated pre-mRNA targets encode
proteins that interact with each other16, suggesting that Nova2
regulates a network of apical–basal polarity regulators and
that AS plays an important role in affecting physical interactions
between these factors during the organization of the vascular
lumen. Hence, the phenotypic changes that we observed on
Nova2 knockdown are likely the integrated effects of several AS
changes that may act in a coordinated and non-redundant
manner.
On the basis of the fact that Nova2 affects both neural and
vascular cell processes, we suggest that Nova2 is a novel member
of the ‘angioneurins’ family3,4. Interestingly, Nova2 is the only
member of the angioneurin family deﬁned so far that functions as
post-transcriptional regulator. Malfunctioning or imbalance in
angioneurin signalling contributes to various neurological
disorders, indicating that non-neuronal defects contribute to
these diseases3. In line with this, in Alzheimer’s disease patients’
vascular dysfunction can be observed before the onset of the
disease, suggesting that vascular alterations might causally
contribute to disease initiation or progression53. Notably,
signiﬁcant AS changes associated with decreased Nova activity
were reported in Alzheimer’s patients54. Since Nova2 is an
autoimmune target in a severe neurodegenerative disorder
paraneoplastic opsoclonus myoclonus ataxia (POMA)55, an
obvious question is whether POMA patients, in addition to
displaying neurological symptoms, also develop vascular
abnormalities.
Methods
Cell culture. ECs were isolated by dissection and dissociation with collagenase type
I (Roche, 1.5mgml 1), DNase (Roche, 25mgml 1) at 37 C for 1 h and by
passing through a 40-mm cell strainer. ECs were immortalized by infecting them
with a retrovirus expressing the polyoma middle-sized T antigen. VEC-null
and VEC-positive were grown as sparse or conﬂuent by placing 500,000 cells in
100- and 35-mm Petri dishes, respectively.
Culture medium of mouse ECs, VEC-null and VEC-positive ECs was DMEM
(GIBCO) with 20% fetal bovine serum (FBS; HyClone), glutamine (2mM, Sigma-
Aldrich), penicillin/streptomycin (100U l 1, Sigma-Aldrich), sodium pyruvate
(1mM, Sigma-Aldrich), heparin (100 mgml 1, from porcine intestinal mucosa;
Sigma-Aldrich) and EC growth supplement (5 mgml 1, made from calf brain;
complete culture medium). HUVECs were isolated from umbilical vein by
treatment with Collagenase (Roche, 0.1%, for 30min at 37 C) and were cultured in
MCDB 131 with EC supplements.
Mouse ES cell culture. To obtain endothelial differentiation of mouse ES cells,
cells were mildly trypsinized and suspended in Iscove’s modiﬁed Dulbecco medium
with 15% FBS, 100Uml 1 penicillin, 100 mgml 1 streptomycin, 450mM mono-
thioglycerol, 10mgml 1 insulin, 50 ngml 1 human recombinant VEGF-A165
(Peprotech Inc.), 2 Uml 1 human recombinant erythropoietin (Cilag AG) and
100 ngml 1 human basic ﬁbroblast growth factor (bFGF) (Genzyme). Cells were
seeded in Petri dishes and cultured for 4 or 7 days at 37 C with 5% CO2 and 95%
relative humidity.
Lentivirus production and transduction. GIPZ Lentiviral Nova2 short-hairpin
RNAs (shRNAs) were obtained from Open Biosystems, while pLenti-GIII-CMV-
humanNova2-HA from THP Medical Products. HEK293T (American Type
Culture Collection, CRL-1573) cells were seeded in DMEM-HIGH supplemented
with 10% FBS without antibiotics in 60-mm Petri dishes (one Petri per infection).
The day after, cells at 60–70% conﬂuence were transfected (calcium phosphate
transfection method) using these quantities of DNA: 5 mg of packaging plasmid,
5 mg of envelope plasmid and 20 mg of Nova2 vectors. After 18 h, the medium was
replaced with growth medium DMEM supplemented with 20% FBS and 1%
penicillin/streptomycin. Cells were incubated for 24 h and the medium containing
the lentiviral particles was harvested, ﬁltered using a 0.45-mm ﬁlter unit and used to
infect the cells.
For viral transduction, mouse EC cells were seeded in 100-mm Petri dishes and
were infected at 70% of conﬂuence. Cells were incubated overnight with the viral
supernatant supplemented with 0.2mM proline and polybrene (ﬁnal concentration
8 mgml 1; Sigma). After 48 h puromycin selection (3 mgml 1) was started and it
was continued until all non-infected control cells died (typically, 5 days).
2D culture. Mouse ECs transduced with lentiviral vectors carrying shRNA for
Nova2 were seeded in 35-mm Petri dishes coated with Gelatin (Difco) 0.1% and
cultured for 72 h. The splitting ratio was such that conﬂuence was reached over-
night after seeding. For immunoﬂuorescence, ECs were ﬁxed with 4% paraf-
ormaldehyde (PFA) and then permeabilized with 0.5% Triton X-100 for 10min.
Blocking (1 h), primary (overnight) and secondary (1 h) antibodies were diluted in
PBS with 2% BSA. The following primary antibodies were used: anti-Par3 (1:100
Millipore), anti-Podocalyxin (1:100 R&D), anti-VE-cadherin (1:100 C-19, sc-6458,
goat, Santa Cruz Biotechnology) and anti-b-catenin (1:50 BD Transduction
Laboratories). Secondary antibodies for immunoﬂuorescence were donkey anti-
bodies to the appropriate species conjugated with Alexa Fluor 488, 555 or 647
(dilution 1:200 or 1:400).
For imaging, charge-coupled device camera on epiﬂuorescence microscope
(Leica) or Leica TCS SP2 confocal microscopy were used. ImageJ (NIH) was
employed for data analysis. Figures were assembled using Adobe Photoshop and
Adobe Illustrator. Only adjustments of brightness and contrast were used in the
preparation of the ﬁgures. For comparison purposes, different sample images of the
same antigen were acquired under constant acquisition settings.
Immunoblot analysis. Cells were lysed in Laemmli buffer and proteins were
separated using SDS–PAGE and analysed with western blotting. The following
primary antibodies were used: anti-Nova2 (1:200 Santa Cruz Biotechnology, C-16),
anti-GAPDH (1:5,000 Abcam; 1:50,000 AbFrontier), anti-Tubulin (1:100,000
Sigma-Aldrich), anti-total-Pak4 (1:1,000 Cell Signaling), anti-phospho-Pak4
(1:1,000 Cell Signaling), anti-haemagglutinin (HA; 1:1,000 Covance), anti-total-
PKCz (1:1,000 Abcam), anti-phospho-PKCz (1:1,000 Cell Signaling) and anti-
Actin (1:500 Santa Cruz Biotechnology). The following secondary antibodies linked
to horseradish peroxidase (Jackson ImmunoResearch) were used: anti-Mouse
(1:10,000), anti-Goat (1:5,000) and anti-Rabbit (1:10,000). Immunostained bands
were detected using the chemiluminescent method (Pierce).
Retinal immunohistochemistry. All animal work using mice was conducted in
accordance with the Swedish Animal Welfare Board at the Karolinska Institutet,
Stockholm, Sweden. Eyes retrieved from pups at P6 were ﬁxed in cold 100% MeOH
and stored at  20 C before dissection. After dissection, retinas were incubated in
5% donkey sera, 1% BSA and 0.5% Triton X-100 in PBS overnight and then
incubated with antibodies towards Nova2 (Santa Cruz Biotechnology, C-16),
PECAM (BD Bioscience, MEC13.3) and ERG (Abcam, ab92513) overnight. For
secondary detection, retinas were incubated with ﬂuorescently conjugated anti-
bodies (Jackson ImmunoResearch) and mounted ﬂat with ProLong Gold
(Invitrogen).
Immunohistochemistry. All procedures involving human samples were approved
by the Istituto Europeo di Oncologia (IEO) Ethical Committee. When possible, a
written informed consent for research use of biological samples was obtained from
all patients, and the research project was approved by the Institutional IEO Ethical
Committee. Immunohistochemistry (IHC) was performed using 3-mm sections
from formalin-ﬁxed and parafﬁn-embedded tissue samples. Samples were rehy-
drated through xylene and graded alcohols. Antigen retrieval was accomplished
using 10mM sodium citrate, 0.05% Tween20, pH 6.0. Samples were then incubated
with 3% H2O2 for 5min, followed by 30min of blocking in 2% BSA and 0.05%
Tween20, and then by the incubation with goat anti-Nova2 (1:100 Santa Cruz
Biotechnology, C-16) overnight at 4 C in 2% BSA and 0.02% Tween20. Immu-
nocomplexes were visualized with LSABþ System-HRP, DAKO (K0690) and
acquired with the Aperio ScanScope system. Slides were counterstained with
haematoxylin for histological evaluation. Double IHC was performed as follows:
antigen retrieval was accomplished using 1mM EDTA, 0.05% Tween. Samples
were then incubated with 3% H2O2 for 5min, followed by 30min of blocking in 2%
BSA and 0.02% Tween20, and then were incubated with a mix of goat anti-Nova2
(1:200) and mouse anti-CD31 (1:60 DAKO, Clone JC70A) in 2% BSA and 0.02%
Tween20 for 2 h at room temperature. Immunocomplexes were visualized with an
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anti-goat horseradish peroxidase (HRP) detection system (Goat-on-Rodent HRP-
Polymer, Biocare Medical), for 30min at RT, followed by incubation with a Goat
Anti-Mouse AP Polymer detection system (MACH 2 Mouse AP-Polymer Biocare
Medical) for 30min at RT. CD31 was visualized in red using the Vulcan Fast Red
Chromogen (Biocare Medical) and Nova2 was visualized in green using the Vina
Green Chromogen Kit (Biocare Medical) according to the manufacturer’s protocol.
Migration assay. To analyse cell migration, the wound-healing technique was
used. Brieﬂy, conﬂuent EC monolayers on a tissue culture dish were wounded by
manually scratching with a pipette tip after an overnight starving, washed with
starving medium and incubated at 37 C for 8 h in complete media containing
Mitomycin C (4mgml 1). The wound-induced cell migration was followed by
staining with ﬂuorescent phalloidin (10 mM, Sigma).
Paracellular ﬂux. Mouse ECs were seeded on 0.4-mm pore size Transwell
Permeable Supports (Corning) cultured in complete culture medium before
assaying permeability. Next, ﬂuorescein isothiocyanate dextran (70 kDa; Sigma)
was added to the medium of the transwell apical compartment. At different times
of incubation, a 50-ml aliquot of the medium was collected from the basal com-
partment, and the paracellular tracer ﬂux was measured as the amount of ﬂuor-
escein isothiocyanate dextran in the medium using a ﬂuorometer.
3D culture in collagen gels. HUVECs were transduced with GIPZ lentiviral
vectors (Open Biosystems) carrying shRNA for Nova2 or control shRNA. Control
and Nova2 knockdown HUVECs were cultured in 3D collagen gel. The ﬁnal cell
density in collagen (3.5mgml 1 ﬁnal concentration collagen type1 from rat tail,
High Concentration, BD Biosciences) was 5 105 cellsml 1. Culture medium was
199 with 1% FCS, Insulin-Transferrin-Selenium supplement (Life Technologies),
50 ngml 1 phorbol myristate acetate, 50 mgml 1 ascorbic acid, 40 ngml 1 VEGF
and 40 ngml 1 bFGF. For confocal microscopy, 190 ml cell suspension in collagen
was used for each microwell (m-slide 80826, Ibidi, Germany). 3D cultures were
ﬁxed with 3% PAF for 35min, quenched with 75mM NH4Cl and 20mM glycine in
PBS, pH 8, for 10min and blocked with 0.7% FSG and 0.3% Triton X-100 PBS
(blocking buffer) for 30min. Primary and secondary antibodies were incubated
overnight at 4C. Primary antibody contained 5% donkey serum. Washes in
blocking buffer were performed over the course of a day at room temperature. For
immunoﬂuorescence, the following primary antibodies were used: anti-Podoca-
lyxin (R&D, 1:400) and anti-Coll IV (AbD Serotech, 1:200). Secondary antibodies
for immunoﬂuorescence were donkey antibodies to the appropriate species
conjugated with Alexa Fluor 488, 555 or 647 (dilution 1:200 or 1:400).
Plasmids. Mouse Pix-a-FL fused to HA-tag was ampliﬁed with primers SG57-F
and SG56-R (Supplementary Table 9) and was cloned in pcDNA3.1(þ ) vector
(Invitrogen), whereas Pix-a-D17 was generated by PCR-mediated mutagenesis of
Pix-a-FL (using primers SG55-F/-R and SG56-F/-R). All constructs were veriﬁed
by sequencing.
RNA extraction and RT–PCR. Total RNA was isolated using the RNeasy Mini Kit
(QIAGEN) according to the manufacturer’s instructions. After treatment with
DNase (Ambion), 2–3mg of RNA was retro-transcribed with mix of d(T)18 oligos
and random hexamers or gene-speciﬁc primers (Supplementary Table 10) and
Superscript III RT (Invitrogen). An aliquot (1/20th) of RT was then PCR-ampliﬁed.
For qPCR, an aliquot of the RT reaction was analysed with QuantiTect SYBR
Green PCR (QIAGEN) by using LyghtCycler 480 (Roche). Target transcript levels
were normalized to those of reference gene. The expression of each gene was
measured in at least three independent experiments. All primers are listed in
Supplementary Tables 6 and 7. AS bands were quantiﬁed using densitometric
analysis.
Pull down of GTP-bound Cdc42. Nova2-depleted and control mouse ECs cul-
tured in 100-mm Petri dishes were analysed for Cdc42 activity by using the Cdc42
Activation Assay Kit (Abcam) according to the manufacturer’s instructions. For
experiments with Pix-a minigenes, cells were transfected with Lipofectamine 3000
(Invitrogen) and grown to reach conﬂuence before the beginning of the pull down.
Zebraﬁsh strains and maintenance. Zebraﬁsh (Danio rerio) from wild-type AB
and transgenic Tg(ﬂi1a:EGFP)y1 (ref. 41) strains were maintained and bred
according to the national guidelines (Italian decree ‘4 march 2014, n.26’). All
experimental procedures were approved by the FIRC Institute of Molecular
Oncology Institutional Animal Care and Use Committee.
In situ hybridization on zebraﬁsh embryos and sections. Zebraﬁsh nova2 cDNA
was ampliﬁed using PCR (primers CG13F and CG13R in Supplementary Table 9)
and cloned into pCRII-TOPO vector (Invitrogen). The antisense RNA probe was
generated using T7 RNA Polymerase and digoxigenin-labelled UTPs (kit from
Roche) and was puriﬁed with the RNeasy Mini Kit (QIAGEN) according to the
manufacturer’s instructions. Whole embryos of different developmental stages
were ﬁxed overnight in 4% PFA, washed in PBS and pre-incubated for 2 h at 63 C
in hybridization buffer. Next, the nova2 probe was added to the mix and incubated
overnight at 63 C. Embryos were then washed in SSC buffer and pre-incubated for
2 h in blocking medium at room temperature. A ratio of 1:2,000 anti-DIG antibody
conjugated with alkaline phosphatase (Roche) was added and incubated overnight
at 4 C. After several PBS washes, embryos were incubated in NBT/BCIP staining
buffer. Stained embryos were then equilibrated in glycerol 85% in PBS overnight at
4 C and were observed with a stereomicroscope equipped with optic ﬁbres. To
prepare 50-mm transversal sections of 48- hpf embryos, previously stained by in situ
hybridization, we cut them in PBS with a vibratome after inclusion in 5% low-
melting agarose. Sections obtained were equilibrated and mounted in glycerol 85%
in PBS on glass slides and observed under a Nikon Upright microscope. All images
were acquired with high-resolution digital cameras (Nikon).
To detect the mRNA expression of Rap1gap and Pix-a/Arhgef6 genes and GFP,
we use 5-mm parafﬁn sections of the head of 48-hpf Tg(ﬂi1a:EGFP)y1 embryos
ﬁxed overnight with 4% PFA in PBS. To orientate embryos in the proper way
before including in parafﬁn and cutting microtome sections, we have pre-included
them in 1% low-melting agarose (in PBS) under a dissecting microscope with optic
ﬁbers, using plastic base moulds of 7mm of diameter. Parafﬁn was removed with
xylene and sections were rehydrated through graded EtOH washes, permeabilized
with Proteinase-K and HCl 2N and were incubated overnight at 64 C in
hybridization mix with DIG-labelled LNA probes for Rap1gap (50-TTCACCTCTT
CACAGACAAGCT-30) and Pix-a/Arhgef6 (50-TAGACGTAGAGGTGTTGG
ACT-30) (designed and produced by Exiqon). Sections were then treated overnight
at 4 C with an anti-DIG antibody (1:2,000 Roche) conjugated with AP and stained
with NBT/BCIP. After several washes in PBS, embryo sections were incubated
overnight at 4 C with mouse anti-GFP antibody (Upstate, 1:200) and labelled
using the Vina Green Chromogen kit (Biocare Medical).
Zebraﬁsh haematoxylin–eosin staining and immunoﬂuorescence. Agarose was
used to embed 24- and 48-h zebraﬁsh embryos before including in parafﬁn and
cutting microtome 10-mm sections. Sections were stained with haematoxylin– eosin
to assess the histological features. For immunoﬂuorescence, parafﬁn was removed
with xylene and the sections were rehydrated in graded alcohol. Antigen retrieval
was carried out using preheated target retrieval solution (pH 6.0) for 45min. Tissue
sections were blocked with FBS serum in PBS for 90min and incubated overnight
with the following primary antibodies: GFP (1:100 Millipore), Phosphohistone H3
(PHH3, 1:100 Millipore), Caspase3 (1:100 Cell Signaling) and Podocalyxin (Podxl2
1:200, kindly provided by Heinz-Georg Belting). Alexa Fluor-conjugated antibodies
were used for the immunodetection, and all sections were counterstained with 4,6-
diamidino-2-phenylindole (DAPI) and visualized using a Confocal microscope
(Leica SP2).
Morpholino injections and RT–PCR of zebraﬁsh embryo. Zebraﬁsh embryos at
one- to two-cell stage were injected with 6.7 ng of an ATG-morpholino antisense
oligonucleotide (Supplementary Table 8), designed to block translation of the
zebraﬁsh nova2 gene (ENSDARG00000017673). To analyse the kinetics and the
pattern of formation of the ISVs, we mounted in 1.2% low-melting agarose in E3
water Tg(ﬂi1a:EGFP)y1-dechorionated embryos at 22 hpf, previously anaesthetized
using 15mg l 1 of tricaine (Sigma). Image acquisition was performed overnight
every 10min with a  40 water immersion objective on a Leica TCS SP2 confocal
microscope. Confocal stacks from each time point were processed for maximum
intensity projections and, subsequently, movies were generated with the Leica LCS
software. To observe and evaluate the shape and function of the heart, we mounted
under a stereomicroscope 48-hpf dechorionated embryos in 3% methyl-cellulose in
E3 water, previously anaesthetized using 15mg l 1 of tricaine (Sigma). Using high-
resolution digital camera (Nikon), we acquired 13-s movies from both control and
nova2 morphant embryos. Total RNA was extracted from 24-hpf pooled embryos
with TRIzol reagent (Invitrogen), puriﬁed with the RNeasy Mini Kit (QIAGEN)
and retro-transcribed with d(T)18 oligo or gene-speciﬁc primer and Superscript III
RT (Invitrogen) and then analysed in PCR for AS modiﬁcation of nova2 targets. To
rescue morphological and vascular defects due to the knockdown of nova2, we
ampliﬁed with primers CG30F/CG13R (Supplementary Table 9) by using RT
generated from Tg(ﬂi1a:EGFP)y1 embryos, a morpholino-resistant zebraﬁsh nova2
cDNA, with six mismatches in the pairing region with the morpholino, which,
however, do not alter the amino-acid sequence of the translated protein. We cloned
this cDNA in pCRII-TOPO vector (Invitrogen) and we transcribed in vitro the
capped mRNA using SP6 mMessage mMachine kit (Ambion). Co-injection in one-
to two-cell stage embryos of 6.7 ng of MO-nova2 and 160 pg of each nova2 mRNAs
was performed. The molecular and morphological changes of nova2 morphants
were scored at 28 hpf.
Generation of new ﬁsh line for endothelial-speciﬁc rescue. To drive Nova2
expression selectively in the zebraﬁsh vascular endothelium, we cloned the mor-
pholino-resistant zebraﬁsh nova2 cDNA into the pTolﬂi1epCherryDest vector56 in
frame with mCherry at the N terminus under the endothelial ﬂi1a enhancer/
promoter ﬂanked by Tol2 transposable elements (pTolﬂi1:nova2-CherryDest).
Fertilized eggs from casper x Tg(ﬂi1a:EGFP)y1 mutant/transgenic line were injected
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with 2 nl of a mixture containing 25 ng ml 1 of the circular plasmid pTolﬂi1:nova2-
CherryDest and 25 ng ml 1 of T2 transposase mRNA. Injected embryos were
selected for simultaneous expression of GFP and mCherry in the vessels, raised to
adulthood and crossed with casper  Tg(ﬂi1a:EGFP)y1 ﬁsh. F1 embryos were
observed under a ﬂuorescent dissecting microscope from days 1 to 5 after
fertilization to select carrier ﬁsh of the new mutant/double transgenic line casper 
Tg(ﬂi1a:EGFP)y1þTg(ﬂi1:nova2-mCherry).
To assay the capability of nova2 mRNA to rescue nova2 morphant phenotype
speciﬁcally in the vessel endothelium, we performed two experiments. Co-injection
of 6.7 ng of MO-nova2, 50 pg of the rescuing DNA construct pTolﬂi1:nova2-
CherryDest and 120 pg of Tol2 transposase mRNA was performed directly into the
cytoplasm of one-cell stage casper  Tg(ﬂi1a:EGFP)y1 embryos. The phenotype of
the vessels of the resulting ‘mosaic’ embryos was scored at 28 hpf. Alternatively,
injection of 6.7 ng of MO-nova2 was performed into one-cell stage casper 
Tg(ﬂi1a:EGFP)y1þTg(ﬂi1:nova2-mCherry) embryos. The phenotype of all the
vessels of the resulting embryos was scored at 28 hpf.
Immunoﬂuorescence staining of zebraﬁsh embryos. Zebraﬁsh embryos from
the Tg(ﬂi1a:EGFP)y1 strain at 48 hpf were dechorionated and ﬁxed in 2% PFA in
PBS, overnight at 4 C. Embryos were then washed four times for 5min in PBST
(PBSþ 0.1% Tween20). Permeabilization in PSBTþ 0.5% Triton X-100 was per-
formed for 30min at room temperature. Embryos were then blocked in a solution
of PBSTþ 0.5% Triton X-100, 10% normal goat serum and 1% BSA for 2 h at room
temperature. Embryos were incubated with primary antibodies in blocking solution
overnight at 4 C. Successively, embryos were washed six times in PBST over 4 h at
room temperature and then incubated with secondary antibodies in blocking
solution, overnight at 4 C. Embryos were washed ﬁnally six times in PBST over 4 h
at room temperature and equilibrated in glycerol 85% in PBS. The following
antibodies were used: mouse anti-GFP (1:2,000 Millipore); rabbit anti-podocalyxin
(1:150 kindly provided by Heinz-Georg Belting); rabbit anti-mouse Alexa-488-
conjugated IgG (1:400); and goat anti-rabbit Alexa 546-conjugated IgG (1:400). For
the microscope analysis, we mounted on slides the trunk and tail regions dissected
from ﬁve to six embryos of each samples. Images were taken with a Leica TCS SP2
confocal microscope, using oil-immersion objective  40.
Generation of nova2 zebraﬁsh mutant by CRISPR/Cas9. To identify the best
target site and to design the single guide RNA (gRNA), we submitted to the ZiFiT
targeter website (http://ziﬁt.partners.org/ZiFiT) the sequence of the ﬁrst exon of the
zebraﬁsh nova2 gene. Oligonucleotides corresponding to the target region (see
Supplementary Fig. 11A and Supplementary Table 11) were annealed and cloned
into the pDR274 gRNA expression vector (Addgene, 42250) immediately upstream
of the crRNA:trascRNA backbone. The nova2 genomic target sequence starts with
two GG nucleotides at the 50 end for efﬁcient transcription from the T7 promoter
and ends with the protospacer-adjacent motif. The correct position of the target
sequence into the pDR274 plasmid was veriﬁed through sequencing, using M13-
Rev primer (Supplementary Table 11). The nova2 gRNA was in vitro transcribed
and puriﬁed from DraI-digested plasmid as template, using the Maxiscript T7 Kit
(Life Technologies). Capped and polyadenylated Cas9 mRNA was in vitro tran-
scribed and puriﬁed from 1 mg of PmeI-digested pMLM3613 Cas9 expression
vector (Addgene, 42251) as a template, using the mMessage mMachine T7 ULTRA
kit (Life Technologies).
A volume of 2 nl of a solution containing B13 ng ml 1 of nova2 gRNA and
B300 ng ml 1 of Cas9 mRNA was co-injected in one-cell stage zebraﬁsh embryos.
On the next day, only embryos with a normal morphological phenotype were
allowed to grow. To evaluate the efﬁciency of Cas9 nuclease activity, genomic DNA
was extracted from 48-hpf single injected embryos and the nova2-targeted genomic
locus was ampliﬁed from genomic DNA of each embryo (primers n2-locus-F and
n2-locus-R in Supplementary Table 11). PCR products were then processed for the
T7 Endonuclease I (T7EI) assay. PCR products were denaturated at 95 C and
rapidly re-annealed using a PCR thermocycler. PCR products were then incubated
for 20min with T7EI enzyme at room temperature, and the digestion products
were visualized on 2% agarose gels. We found that 95% of the injected embryos had
mutations at the level of the nova2 target site.
To analyse the kinds of mutations obtained at the level of the nova2 locus, we
sequenced PCR products, cloned into pCRII-TOPO plasmid using the TOPO TA
cloning kit (Life Technologies), ampliﬁed from genomic DNA extracted from ﬁn-
fragments of 2-month ﬁshes. Among these ﬁshes, we isolated those carrying the
mutation also in the germline and subsequently we selected from their progeny ﬁshes
with nonsense or missense mutations in the nova2 locus. A male carrying a nonsense
mutation was crossed with a female from the Tg(kdrl:EGFP) line to generate a double
EGFP transgenic-nova2 mutant line expressing the EGFP reporter in vascular ECs
and allowing to characterize the vascular phenotype of nova2 mutants.
o-dianisidine staining. For histochemical staining of haemoglobin, 72 hpf live
embryos were incubated with o-dianisidine staining solution (40% ethanol, 0.01M
sodium acetate, 0.65% H2O2, 0.6mgml 1 o-dianisidine (Sigma, D-9143) for
15min. Embryos were then washed with PBS, post-ﬁxed in 4% PFA in PBS
overnight at 4 C and stored in 85% glycerol for microscope analysis.
RNAseq and splicing analysis. RNAseq was conducted on two control and two
Nova2-depleted ECs. Samples were sequenced on Illumina HiSeq2500 (average of
B93 million, 100-nucleotide (nt) paired-end reads for each run). We employed
vast-tools32 to identify and quantify all major types of AS events, including single
and multiple cassette exons and microexons, alternative 50 and 30 splice sites and
alternatively retained introns, from each RNAseq sample. vast-tools map reads to
comprehensive sets of exon–exon junctions (EEJs) and exon–intron junctions
(EIJs) to derive alternative sequence inclusion levels (PSIs, ‘Percent Spliced In’, for
exons; PIR, ‘Percent Intron Retention’, for introns)57. We then compared the two
replicates of Nova2 knockdown ECs versus control ECs. Differentially regulated AS
events were deﬁned as those showing an absolute DPSIZ15 between knockdown
and control means and a DPSIZ5 between the ranges of the two groups. Only AS
events with a minimum read coverage in all four samples were compared, which
was deﬁned as:
– For cassette exons (except for those quantiﬁed using the microexon pipeline,
see Irimia et al.32 for details): (i) Z10 reads mapping to the sum of exclusion
EEJs or (ii)Z10 reads mapping to one of the two inclusion EEJs andZ5 to the
other inclusion EEJ.
– For microexons: (i) Z10 reads mapping to the sum of exclusion EEJs or (ii)
Z10 reads mapping to the sum of inclusion EEJs.
– For intron retention: (i)Z10 reads mapping to the sum of skipping EEJs or (ii)
Z10 reads mapping to one of the two inclusion EIJs and Z5 to the other
inclusion EIJ.
– For alternative 30 and 50 splice sites:Z10 reads mapping to the sum of all EEJs
involved in the speciﬁc event.
Additional ﬁltering was used to remove intron retention events with a binomial
P value score above 0.05 in any of the four samples57.
This resulted in 365 differentially regulated AS events (Supplementary Fig. 4
and Supplementary Table 1), which were subdivided according to the predicted
impact of Nova2 knockdown on the coding sequence (Supplementary Fig. 5A):
(i) AS events predicted to generate protein isoforms both when Nova2 is present or
depleted (150, 41.1%); (ii) AS events predicted to trigger nonsense-mediated decay
(NMD) or create a truncated protein when Nova2 is present (135, 37.0%); (iii) AS
events predicted to trigger NMD or to create a truncated protein when Nova2 is
absent (33, 9.0%); (iv) AS events in noncoding regions (40, 11.0%); and (v) AS
events not able to be categorized into previous categories (7, 2%).
GO analysis was performed for each of the subdivided groups using ClueGO58.
The background reference was based on multiexonic genes with the same
minimum read coverage in the endothelium used above. Two categories had
signiﬁcant enrichment (P valueo0.05), those generating protein isoforms ((i) 49
terms enriched in 150 genes; Supplementary Fig. 5B) and those predicted to trigger
NMD/disrupted proteins when Nova2 is included ((ii) 15 terms enriched in 135
genes; Supplementary Fig. 5C). Detail of P values (as calculated by ClueGO) are
found in Supplementary Table 2.
To compare AS events that show differential inclusion on Nova2 knockdown in
ECs to those regulated by Nova proteins in neural cells, we used the 325 cassette
exons previously predicted to be Nova targets in the brain33 (Supplementary
Table 3). Nearly all (319/325) exons could be matched to vast-tools AS event IDs
based on the exact splice site coordinates and ofﬁcial gene symbols. Of these, 195/
319 (61%) had enough read coverage to conﬁdently derive inclusion estimates
(PSIs) in all four EC RNAseq samples. From these, 28/195 (14.4%) exons showed a
DPSIZ10 on Nova2 knockdown in ECs in the same direction as previously
predicted for Nova proteins in the brain, compared with only 2/195 (1%) in the
opposite direction (Supplementary Fig. 6). This overlap between Nova-regulated
exons in endothelial and neural cells is highly signiﬁcant (P¼ 1.93e 11,
hypergeometric test; background event set corresponded to 14,970 cassette exons
with a minimal read coverage in the endothelium as described above and in genes
with a cRPKM42 in neurons19). Moreover, several methodological differences
suggest that the actual overlapping of Nova2 regulation between endothelial and
neural cells may be even higher. First, predictions of Zhang et al.33 include Nova1
and Nova2 targets, which may not be fully redundant. Second, exons described in
Zhang et al. are predicted to be Nova protein targets based on Nova binding and
presence of binding sites, among others. However, only half of the full set of Nova
targets shows measurable differences in PSI in Nova knockout mice33. Finally,
Nova2 proteins may use different cofactors that may be differentially expressed
between endothelial and neural cells.
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